Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
35650,"Amgen Inc.",CA,100000000203,5000.00,02/05/2015,"Cash or cash equivalent",297533118,Repatha,"","LAPLACE2 Combination Therapy","",""
35650,"Takeda Development Center Americas, Inc.",IL,100000000338,1414.00,08/26/2013,"Cash or cash equivalent",106110930,Actos,"","Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD","",""
35650,"Takeda Development Center Americas, Inc.",IL,100000000338,825.99,08/26/2013,"Cash or cash equivalent",106110927,Actos,"","Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD","",""
35650,"Amgen Inc.",CA,100000000203,151.88,06/07/2015,"In-kind items and services",297533162,Repatha,"","MENDEL2 Monotherapy","",""
35650,"GlaxoSmithKline, LLC.",NC,100000005449,92.20,05/28/2014,"Cash or cash equivalent",208680858,"","","A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE","",""
35650,"Amgen Inc.",CA,100000000203,79.66,06/07/2015,"In-kind items and services",297533160,Repatha,"","MENDEL2 Monotherapy","",""
35650,"Amgen Inc.",CA,100000000203,43.64,08/30/2015,"In-kind items and services",297532754,Repatha,"","Consistent and Clinically Equivalent LDL-C Reduction with Q2W and QM in Phase 3","",""
35650,"Amgen Inc.",CA,100000000203,15.94,10/12/2015,"In-kind items and services",297532868,Repatha,"","Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes","",""
35650,"GlaxoSmithKline, LLC.",NC,100000005449,1.08,05/28/2014,"Cash or cash equivalent",208680862,"","","A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE","",""
